Pharmacogenetics of infliximab in Crohn's disease

Dideberg, Vinciane; Louis, Edouard; Bours, Vincent

doi:10.1007/BF02961799

Request a copy

Article (Scientific journals)

Pharmacogenetics of infliximab in Crohn's disease

Dideberg, Vinciane; Louis, Edouard; Bours, Vincent

2007 • In Acta Endoscopica, 37 (4), p. 521-530

Peer reviewed

Permalink
https://hdl.handle.net/2268/25881

DOI
10.1007/BF02961799

Files (2)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Pharmacogenetics of infl... Acta end 2007 521-530.pdf

Publisher postprint (263.14 kB)

Request a copy

Full Text Parts

PostpAutAO-Pharmacogenetics of infliximab in... 2007-Acta End traité OCR.pdf

Author postprint (218.87 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Crohn's disease; infliximab; pharmacogenetics

Abstract :

[en] Pharmacogenetic studies will certainly contribute to a better management of medication in inflammatory bowel diseases. Infliximab is the most efficient drug in refractory and fistulising Crohn's disease. However, about one third of the patients do not respond to this treatment. Several studies have been performed to identify predictive factors of the response to infliximab in CD. We attempt to summarize the current knowledge on the use of infliximab in CD and focus on the result of these studies and more particularly on pharmacogenetic aspects.

Disciplines :

Surgery

Author, co-author :

Dideberg, Vinciane ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Bours, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique générale et humaine

Language :

English

Title :

Pharmacogenetics of infliximab in Crohn's disease

Publication date :

2007

Journal title :

Acta Endoscopica

ISSN :

0240-642X

eISSN :

1242-1383

Publisher :

Endoscopica, Nancy, Belgium

Volume :

Issue :

Pages :

521-530

Peer reviewed :

Peer reviewed

Available on ORBi :

since 19 October 2009

Statistics

Number of views

115 (7 by ULiège)

Number of downloads

113 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Thompson NP, Driscoll R, Pounder RE, Wakefield AJ. Genetics versus environment in inflammatory bowel disease, results of a British twin study. BMJ 1996; 312: 95-96.
Tysk C, Lindberg E, Jarnerot G, Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988; 29: 990-96.
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357: 1925-28.
Hugot J-P, Chamaillard M, Zouali H, Lesage S, Cezard J-P, Belaiche J, Aimer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel J-F, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411: 599-603.
Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar J-P, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease, the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
Van den Brande J, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn's disease. J Rheumatol Suppl 2005; 74: 26-30.
Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S-I, Kikuchi Y, Otsuka J, Okamura S, Fujita S, Harada M. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-[alpha]. Gastroenterology 2005; 128: 376-92.
Lugering A, Schmidt M, Lugering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab Induces Apoptosis in Monocytes From Patients With Chronic Active Crohn's Disease by Using a Caspase-Dependent Pathway. Gastroenterology 2001; 121: 1145-57.
Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-11.
Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-(alpha) Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation; A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease. J Immunol 2006; 176: 2617-24.
Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250-9.
Targan SR HS, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 9: 1029-35.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease. N Engl J Med 1999; 340: 1398-1405.
Rutgeerts P DHG, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L VHR, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. N Engl J Med 2004; 350: 876-85.
Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor {alpha}-Neutralizing Agent. N Engl J Med 2001; 345: 1098-1104.
Colombel J-F, Loftus J, Edward V., Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease, The Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P. Autoimmunity associated with anti-tumor necrosis factor [alpha] treatment in Crohn's disease, a prospective cohort study. Gastroenterology 2003; 125: 32-9.
Parsi MA, Achkar J-P, Richardson S, Katz J, Hammel JP, Lashner BA, Brzezinski A. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C. Infliximab in the treatment of Crohn's disease. Predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 577-83.
Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharm Ther 2003; 17: 1451-7.
Vermeire S, Louis E, Carbonez A, Assche G, Noman M, Belaiche J, Vos M, Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. The American Journal of Gastroenterology 2002; 97: 2357-63.
Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "On Demand" Therapy with Infliximab in Crohn's Disease. Clinical Experience with 400 Infusions. The American Journal of Gastroenterology 2003; 98: 608-12.
Lionetti P, Bronzini F, Salvestrini C, Bascietto C, Canani RB, De Angelis GL, Guariso G, Martelossi S, Papadatou B, Barabino A. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharm Ther 2003; 18: 425-31.
Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ. Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease. Am J Gastroenterol 2006; 101: 1030-8.
Martinez-Borra J, Lopez-Larrea C, Gonzalez S, Fuentes D, Dieguez A, Deschamps EM, Perez-Pariente JM, Lopez-Vazquez A, Francisco R, Rodrigo L. High serum tumor necrosis factor-alpha, levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97: 2350-6.
Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J. A positive response to infliximab in Crohn disease, association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-24.
Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR. ANCA Pattern and LTA Haplotype Relationship to Clinical Responses to Anti-TNF Antibody Treatment in Crohn's Disease. Gastroenterology 2001; 120: 1347-55.
Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Bours V. Lymphotoxin alpha gene in Crohn's disease patients, absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics 2006; 16: 369-73.
Mascheretti S, Hampe J, Kuhbacher T, Herfarth H, Krawczak M, Folsch UR, Schreiber S. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infliximab. Pharmacogenomics J 2002; 2: 127-36.
Dideberg V, Theatre E, Farnir F, Vermeire S, Rutgeerts P, De Vos M, Belaiche J, Franchimont D, Van Gossum A, Louis E, Bours V. The TNF/ADAM 17 system, implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's Disease. Pharmacogenet Genomics 2006 (in press).
Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P. Tumour necrosis factor-alpha, receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharm Ther 2004; 20: 303-10.
Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schubert S, Olson A, Bao W, Folsch UR, Schreiber S. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene, an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-15.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 123: 106-11.
Urcelay E, Mendoza JL, Martinez A, Fernandez L, Taxonera C, Diaz-Rubio M, de la Concha EG. IBD5 polymorphisms in inflammatory bowel disease, association with response to infliximab. World J Gastroenterol 2005; 11: 1187-92.
Louis E, El Ghoul Z, Vermeire S, Dall'Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel J-F, Watier H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharm Ther 2004; 19: 511-19.
Willot S, Vermeire S, Ohresser M, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Franchimont D, Colombel JF, Watier H, Louis E, Siddiqui MA, Scott LJ, Mascheretti S, Schreiber S, Chaudhary R, Ghosh S, Efthimiou P, Markenson JA, van den Brande J, Hommes DW, Peppelenbosch MP, Sandborn WJ, Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F, McNamara DA, Brophy S, Hyland JM, Su C, Lichtenstein GR, D'Haens G, Hlavaty T. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics 2006; 16: 37-42.
Hlavaty T, Pierik M, Henckaerts L, Ferrante M, Joossens S, Schuerbeek N, Noman M, Rutgeerts P, Vermeire S. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharm Ther 2005; 22: 613-26.